Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Qiagen ( (QGEN) ).
Qiagen disclosed that the Dutch markets regulator AFM has published a voting rights notification showing that BlackRock, Inc. and its various asset management affiliates collectively hold a substantial position in Qiagen. The filing indicates that BlackRock’s total stake amounts to 10.52% of Qiagen’s share capital and 11.66% of voting rights through a mix of real and potential holdings, primarily held indirectly.
The announcement highlights the continued interest of one of the world’s largest asset managers in Qiagen, underscoring the company’s appeal to global institutional investors. While Qiagen stresses it is not responsible for the accuracy of the AFM data, the disclosed levels of ownership signal significant institutional backing that may influence future shareholder dynamics and governance discussions.
The most recent analyst rating on (QGEN) stock is a Buy with a $51.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V., based in Venlo, Netherlands, is listed in Frankfurt and on the NYSE and operates in the life sciences and diagnostics sector, providing sample and assay technologies for molecular testing. Its shares are traded on several European exchanges and in the U.S., making it a widely held stock among international institutional investors.
Average Trading Volume: 2,280,437
Technical Sentiment Signal: Sell
Current Market Cap: $8.89B
For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.